Second Sight Medical Products (NASDAQ:EYES) Upgraded to Hold at ValuEngine

ValuEngine upgraded shares of Second Sight Medical Products (NASDAQ:EYES) from a sell rating to a hold rating in a research note released on Tuesday, ValuEngine reports.

Separately, Zacks Investment Research raised Second Sight Medical Products from a hold rating to a buy rating and set a $1.00 price target for the company in a report on Wednesday, November 20th.

Shares of NASDAQ:EYES opened at $0.86 on Tuesday. Second Sight Medical Products has a 1 year low of $0.63 and a 1 year high of $1.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.83 and a quick ratio of 2.66. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.81.

Second Sight Medical Products (NASDAQ:EYES) last released its earnings results on Thursday, November 14th. The medical device company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $0.94 million. Second Sight Medical Products had a negative return on equity of 201.34% and a negative net margin of 743.86%. Equities analysts anticipate that Second Sight Medical Products will post -0.29 EPS for the current year.

About Second Sight Medical Products

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

Read More: Quiet Period

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit